Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248432 | 0.92 | HDAC6 (0.66) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6421798 | 0.89 | HDAC1 (0.55) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6421094 | 0.89 | PTGDR2 (0.59) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6424243 | 0.89 | HDAC1 (0.55) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6423329 | 0.88 | HDAC1 (0.55) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6421118 | 0.87 | HDAC1 (0.55) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6423858 | 0.87 | HDAC1 (0.53) | HDAC1HDAC6KRASPTGDR2CHRM2 | |
| SCHEMBL6421345 | 0.84 | HDAC1 (0.67) | HDAC1HDAC6 | |
| SCHEMBL6420742 | 0.83 | HDAC1 (0.54) | HDAC1HDAC6KRASCHRM2CHRM4 | |
| SCHEMBL6422016 | 0.83 | HDAC1 (0.54) | HDAC1HDAC6KRASCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HDAC1 1695/4885HDAC6 653/4885KRAS 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.